Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A new revision entry v3.3.2 was added to the record history. The older revision v3.2.0 was removed from the history list.
    Difference
    0.1%
    Check dated 2025-11-26T07:17:12.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The government funding status notice banner was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2025-11-19T08:09:59.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    This change appears to be a cosmetic update to the Record History view with no modification to core study information; to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-10-28T02:52:50.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    - Added a prominent notice about potential outdated information due to lapse in funding and updated operating status references, plus a link to operating-status details. - Updated version to v3.2.0. - Removed old version reference v3.1.0.
    Difference
    12%
    Check dated 2025-10-06T15:59:22.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.3%
    Check dated 2025-09-29T09:54:16.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Updated to v3.0.2; removed v3.0.1 and the Back to Top link. No substantive changes to core content, pricing, stock, or time-slot information.
    Difference
    0.7%
    Check dated 2025-09-15T00:12:17.000Z thumbnail image

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.